STTK Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Shattuck Labs Inc (STTK) is not a strong buy for a beginner investor with a long-term strategy at this time. Despite positive developments in reducing losses and promising Phase 1 clinical trials for SL-325, the stock's overbought technical indicators, lack of strong proprietary trading signals, and potential short-term downside risks suggest holding off on immediate investment.
The stock is currently in an overbought condition with an RSI of 91.329, indicating potential for a pullback. MACD is positive and expanding, suggesting bullish momentum. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Current price is above R1 (5.587) and approaching R2 (6.104), signaling limited upside in the short term.
Analysts have upgraded the stock to 'Buy' and 'Overweight' ratings with price targets of $14 and $15, citing the potential of SL-
Financial losses have significantly narrowed, reflecting improved cost management.
Sufficient cash runway into 2029, reducing liquidity concerns.
Phase 1 trial for SL-325 is progressing well, with final cohort completion expected by Q2 2026.
The stock is overbought based on RSI, increasing the likelihood of a short-term pullback.
Historical financial performance shows declining revenue and net income YoY.
Stock trend analysis suggests a 60% chance of a -7.33% decline in the next week.
No significant hedge fund or insider trading activity to indicate strong institutional confidence.
For Q4 2025, net loss improved to $12.6M from $18.7M YoY, and full-year 2025 net loss narrowed to $48.8M from $75.4M in 2024. Cash reserves increased to $78.1M, providing a runway into 2029. However, revenue dropped significantly in Q3 2025 (-66.63% YoY), and EPS declined by 57.58% YoY.
Recent analyst ratings are bullish, with Needham and Piper Sandler assigning 'Buy' and 'Overweight' ratings, respectively, and price targets of $14 and $15. Analysts are optimistic about SL-325's potential efficacy and safety profile in treating inflammatory bowel disease.
